European journal of pharmacologyHumansTrastuzumabMyocytesCardiacErb-b2 Receptor Tyrosine Kinases
Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes.
Ana Pozo-Agundo, Sonia García-Rodríguez, Alba Antúnez-Rodríguez, Lucía Chica-Redecillas, Romina Beatriz Cejas, Davi Lyra-Leite, Patricia Porras-Quesada, Javier Gómez-Sánchez, Benito Mirón-Pozo, María Jesús Álvarez-Cubero, Paul W Burridge, Francisco Martin, Luis Javier Martínez-González, Cristina Lucía Dávila-Fajardo
Published: 202610.1016/j.ejphar.2025.178484
Abstract
AIMS: Treatment of HER2 positive (HER2+) breast cancer has significantly improved since the development of trastuzumab. However, approximately 30 % of patients develop trastuzumab-induced cardiotoxicity (TIC) manifested as a decrease in left ventricu…
Preview only. Read the full abstract at the source